Article ID Journal Published Year Pages File Type
2406940 Vaccine 2008 6 Pages PDF
Abstract
Mucosal vaccine formulations based on purified recombinant C280 γ-Intimin and EspB (Escherichia coli secreted protein B) from enterohaemorragic E. coli co-administered with a pegylated derivative of the TLR2/6 agonist MALP-2 (macrophage-activating lipopeptide) as adjuvant were evaluated in BALB/c mice. After intranasal vaccination, strong humoral and cellular immune responses were observed against C280 γ-Intimin and EspB. Sera of immunized mice inhibit bacterial haemolytic activity in vitro. Antigen-specific T-cell proliferation, IL-4, IL-2 and IFN-γ producing cells, and secretory IgA were mostly detected in animals receiving MALP-2 as adjuvant. These results suggest that C280 γ-Intimin and EspB are good candidate antigens to be incorporated into mucosal vaccines against this important pathogen.
Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , , , , , ,